BRIEF—Lixiana results support use in clinical practice

Japanese drugmaker Daiichi Sankyo (TYO: 4568) has announced results from ELIMINATE-AF, a study comparing once-daily Lixiana (edoxaban) 60 mg to uninterrupted vitamin K antagonists (VKA) in atrial fibrillation (AF) patients undergoing catheter ablation.

The study met primary efficacy and safety objectives, demonstrating low thromboembolic and bleeding event rates.

This data was presented on Monday during a late-breaker session at EHRA 2019, the annual congress of the European Heart Rhythm Association.